<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[161, 166] VZV antibody geometric mean titer<br>[174, 179] VZV antibody geometric mean rise<br>[190, 198] incidence of vaccine-related serious adverse experiences<br>[235, 242] GMT ratio (refrigerated formulation/frozen formulation)<br>[265, 270] vaccine-related serious AEs<br>[288, 294] frequencies of injection-site AEs<br>[321, 325] frequencies of systemic AEs<br></td>
<td width=33%>
[133, 142] Varicella-zoster virus (VZV) antibody responses<br>[161, 166] VZV antibody geometric mean titer<br>[174, 179] VZV antibody geometric mean rise<br>[190, 201] incidence of vaccine-related serious adverse experiences (AEs)<br>[222, 223] GMTs<br>[235, 242] GMT ratio (refrigerated formulation/frozen formulation)<br>[256, 257] GMRs<br>[265, 270] vaccine-related serious AEs<br>[288, 294] frequencies of injection-site AEs<br>[321, 325] frequencies of systemic AEs<br></td>
<td width=33%>
[133, 142] Varicella-zoster virus (VZV) antibody responses<br>[161, 172] VZV antibody geometric mean titer (GMT; day 28)<br>[174, 187] VZV antibody geometric mean rise (GMR; days 1 to 28)<br>[190, 201] incidence of vaccine-related serious adverse experiences (AEs)<br>[221, 223] similar GMTs<br>[234, 242] estimated GMT ratio (refrigerated formulation/frozen formulation)<br>[256, 257] GMRs<br>[264, 272] No vaccine-related serious AEs were reported<br>[278, 280] safety profiles<br>[288, 294] frequencies of injection-site AEs<br>[317, 320] generally mild.<br>[321, 325] frequencies of systemic AEs<br>[335, 339] vaccine-related AEs<br></td>
</tr>
